key: cord-0261476-1w3l1jch authors: Pathak, A.; Singh, S.; Patel, S. S.; Fatima, N.; Garg, A.; Ghoshal, U.; Sahu, C. title: Prevalence and effect of bacterial co-infections on clinical outcomes in hospitalized COVID-19 patients at a tertiary care centre of India date: 2021-08-07 journal: nan DOI: 10.1101/2021.08.06.21261695 sha: e4e0aab0f7f505b7f899a9965a1f015483a95baa doc_id: 261476 cord_uid: 1w3l1jch Abstract Background: Bacterial co-infections are a leading cause of morbidity and mortality during viral infections including COVID-19. Systematic testing of COVID-19 patients having bacterial co-infections is essential to select the correct antibiotic for treatment in order to reduce mortality and also prevent spread of antimicrobial resistance (AMR). The present study aims to evaluate the prevalence, demographic parameters, antibiotic sensitivity patterns and outcomes in hospitalized COVID-19 patients with bacterial co-infections. Methods: A total of 1019 COVID-19 patients were selected for the study. We analyzed the prevalence, antibiotic sensitivity pattern and clinical outcomes in COVID-19 patients having bacterial co-infections. Results: Out of a total 1019 COVID-19 patients screened, 5.2% of patients demonstrated clinical signs of bacterial co-infection. Bacteremia was found in majority of the patients followed by respiratory and urinary infections. Escherichia coli, Pseudomonas aeruginosa and Klebsiella spp. were most common isolates among the Gram-negative and Coagulase-negative Staphylococci (CONS) and Staphylococcus aureus among the Gram-positive bacterial infections. Antibiotic sensitivity profiling revealed that colistin, imipenem and fosfomycin were the most effective drugs against the Gram-negative isolates while vancomycin, teicoplanin and doxycycline against the Gram-positive isolates. Analysis of clinical outcomes revealed that the mortality rate was higher (39%) among the patients with bacterial co-infections as compared to the group without co-infection (17%). Conclusions: This study reveals that the rate of bacterial co-infections is significantly increasing among COVID-19 patients and leading to increase in mortality. Systematic testing of bacterial co-infections is therefore essential in COVID-19 patients for better clinical outcomes and to reduce AMR. The human race has witnessed the emergence of four severe viral outbreaks in the last two Super-infection with bacterial pathogens has been identified in various viral respiratory 68 illnesses in the past and contributed to significant rates of morbidity and mortality [5] [6] [7] . 69 Mortality has been reported to be as high as 20-30% in such cases of super-infection [7, 8] . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261695 doi: medRxiv preprint hospitalization on which bacterial culture was sent, antibiotic susceptibility profiles of the 100 bacterial isolates, length of hospital stay and clinical outcomes in the patients. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261695 doi: medRxiv preprint 7 the other bacteriological samples. Bacteremia was seen in majority of the COVID-19 positive 148 patients; followed by respiratory and urinary symptoms. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. The current study stressed the prevalence of bacterial co-infections to be higher among the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261695 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261695 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261695 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261695 doi: medRxiv preprint Three Emerging Coronaviruses in Two Decades COVID-19 (Novel Coronavirus 280 2019) -recent trends Transmission of SARS-CoV-2: Implications for infection 282 prevention precautions Molecular immune pathogenesis and diagnosis of 286 COVID-19 Rate and influence of respiratory virus co-infection on 288 pandemic (H1N1) influenza disease is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.06.21261695 doi: medRxiv preprint